

Pátek 18. května 2018/Friday May 18, 2018

Velká zasedací místnost děkanátu 1. LF UK, Na Bojišti 3, Praha 2
Large meeting room of Dean's Office Building, 1. LF UK, Na Bojišti 3, Praha 2



1. LÉKAŘSKÁ
FAKULTA
Univerzita Karlova



Jan T. Vilcek

Is Research Professor, Department of Microbiology and Professor Emeritus of Microbiology, Department of Microbiology NYU School of Medicine, USA. He was born in Bratislava, Czechoslovakia (now Slovakia), where he also received his M.D. and Ph.D. degrees. Dr. Vilcek has devoted his entire career to the study of cytokines and their role in the control immune responses and host defenses. He is among the earliest investigators of interferon, the first cytokine to be molecularly characterized. Dr. Vilcek and his colleagues were the first to show that there are two distinct families of interferons – now called alpha and beta interferons. Dr. Vilcek is a pioneer of translational medicine and biologic therapeutics. His studies of tumor necrosis factor (TNF) were instrumental in the development of Remicade/infliximab, the first approved drug of a new class of therapeutics called TNF blockers, used in the treatment of autoimmune inflammatory diseases. He has published more than 350 papers in scholarly journals and is a named inventor of 46 U.S. patents.

Dr. Vilcek's honors include the Albert Gallatin Medal from NYU, Gold Medal from Charles University, and Outstanding American by Choice Award from the U.S. Citizenship and Immigration Services; he is a Fellow of the American Association for the Advancement of Science, and received honorary degrees from Comenius University, CUNY Graduate Center, NYU, and Slovak Academy of Sciences. He is Chairman and CEO of The Vilcek Foundation, devoted to raising awareness of the contribution of immigrants to science and the arts in the U.S. In 2013 he received the National Medal of Technology and Innovation from President Barack Obama, honor granted to American inventors and innovators who have made significant contributions to the development of new and important technology.

9.45 Registration for students

10.00 – 11.30 **Infliximab: How a TNF inhibitor advanced from modest beginnings to unforeseen therapeutic successes**

Infliximab was the first TNF antagonist and the first cytokine antagonist successfully used in patients. A monoclonal antibody against human tumor necrosis factor (TNF) that became the core of the biologic drug infliximab/Remicade was generated in the research laboratory of dr. Vilcek. The success of infliximab spurred the development and regulatory approval of other cytokine antagonists used in the treatment of numerous inflammatory diseases. The lecture will review the rationale, molecular mechanisms of action, benefits and shortcomings of the therapeutic use of TNF antagonists and other cytokine antagonists in medicine.

Přednáškové odpoledne je součástí kurzu „Novinky v biomedicinském výzkumu“, který je jeden z doporučených povinně volitelných kurzů pro Ph.D. studenty oboru Biochemie a patobiochemie (Oborová rada 04) a Fyziologie a patofyziologie člověka (Oborová rada 05). Účastníci na konci kurzu získají zápočet. Kurz je sestaven z přednášek zahraničních a domácích světově uznávaných odborníků zabývajících se molekulovými mechanismy etiologie, patogeneze a terapie chorob. Vítání jsou i studenti jiných oborů a zájemci z řad vědeckých pracovníků a lékařů.

Contact information:

Doc. MUDr. Jan Živný, Ph.D., jzivny@lf1.cuni.cz, tel: 22496-5865

Prof. MUDr. Stanislav Štípek, DrSc., stipekst@lf1.cuni.cz, tel: 22496-4283